Alumis’ (ALMS) Neutral Rating Reiterated at HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Alumis (NASDAQ:ALMS) in a research report released on Monday,Benzinga reports. The brokerage currently has a $25.00 price objective on the stock.

A number of other analysts have also recently issued reports on ALMS. Citigroup restated a “buy” rating on shares of Alumis in a research report on Tuesday, May 19th. Chardan Capital raised their target price on Alumis from $38.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, May 19th. Guggenheim lifted their price target on shares of Alumis from $32.00 to $34.00 and gave the stock a “buy” rating in a research note on Friday, May 15th. Morgan Stanley reissued an “overweight” rating and issued a $39.00 price target on shares of Alumis in a report on Friday, May 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Alumis in a research note on Tuesday, July 7th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $40.30.

Alumis Price Performance

ALMS stock opened at $27.12 on Monday. Alumis has a twelve month low of $3.76 and a twelve month high of $31.35. The company has a market cap of $3.46 billion, a PE ratio of -13.70 and a beta of -0.69. The business’s 50-day simple moving average is $25.37 and its 200 day simple moving average is $25.22.

Alumis (NASDAQ:ALMS) last posted its quarterly earnings results on Thursday, May 14th. The company reported ($0.74) EPS for the quarter, missing the consensus estimate of ($0.73) by ($0.01). Alumis had a negative net margin of 2,825.70% and a negative return on equity of 88.79%. The firm had revenue of $1.74 million during the quarter, compared to analyst estimates of $2.10 million. On average, equities research analysts anticipate that Alumis will post -2.87 EPS for the current year.

Insiders Place Their Bets

In related news, insider Sanam Pangali sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, July 6th. The stock was sold at an average price of $28.00, for a total transaction of $140,000.00. Following the completion of the transaction, the insider owned 11,111 shares in the company, valued at $311,108. This trade represents a 31.03% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO John R. Schroer sold 3,282 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $26.37, for a total value of $86,546.34. Following the completion of the sale, the chief financial officer directly owned 24,718 shares in the company, valued at approximately $651,813.66. This represents a 11.72% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 19,953 shares of company stock worth $534,311 in the last 90 days. 33.70% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Alumis

Several institutional investors and hedge funds have recently made changes to their positions in the company. Russell Investments Group Ltd. increased its position in shares of Alumis by 320.9% during the 3rd quarter. Russell Investments Group Ltd. now owns 6,419 shares of the company’s stock worth $26,000 after purchasing an additional 4,894 shares in the last quarter. New York State Common Retirement Fund boosted its position in Alumis by 173.7% in the second quarter. New York State Common Retirement Fund now owns 11,767 shares of the company’s stock valued at $35,000 after buying an additional 7,467 shares in the last quarter. KBC Group NV acquired a new position in Alumis in the first quarter valued at about $42,000. Strs Ohio grew its stake in Alumis by 300.0% during the first quarter. Strs Ohio now owns 2,000 shares of the company’s stock worth $44,000 after buying an additional 1,500 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its stake in Alumis by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,724 shares of the company’s stock worth $46,000 after buying an additional 979 shares during the last quarter.

Alumis News Roundup

Here are the key news stories impacting Alumis this week:

• Neutral Sentiment: HC Wainwright reaffirmed its “Neutral” rating on Alumis, indicating the analyst does not currently see a strong enough catalyst to support a more bullish view. HC Wainwright Reaffirms Neutral Rating for Alumis
• Negative Sentiment: Six company insiders, including CFO John R. Schroer, sold a combined 14,953 shares of Alumis on August 3 at an average price of $26.37, generating approximately $394,311 in proceeds. The sales reduced individual holdings by roughly 1.28% to 12.28%; the CFO’s position declined 11.72%. While insider sales can reflect personal financial planning rather than a change in business outlook, the concentration of sales may weigh on investor sentiment. The transactions were reported in SEC filings for Read More., Read More., Read More., Read More., Read More., and Read More..

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.